Clinical research continues to evolve at an impressive pace. Digital technologies streamline data capture, biomarkers deepen biological insight, and innovative trial designs broaden access for diverse populations. These advances have unquestionably accelerated development and expanded participant reach. Still, across all this progress, one dimension consistently shapes outcomes yet remains underrepresented in planning, modeling, and oversight: patient behavior. Behavioral factors like motivation,
clinical trials
We are pleased to announce that Cognivia will participate in the Fortrea Innovation & Technology Summit in Boston on April 7, 2026. Our CEO, Dominique Demolle, will join the industry panel: “User Experience and Adoption Strategies: Why a Great Product Is Only One Factor in Success.” Speakers: This panel will explore how user experience, adoption
We are pleased to share that Cognivia will take part in the SAPA Annual Conference in Philadelphia on March 21, 2026. Our CEO, Dominique Demolle, will join the round‑table discussion: “From Data to ROI: How AI Impacts the Bottom Line of Drug Development.” Speakers: This session will explore how AI‑driven insights translate into measurable value
Cognivia launches the world’s first early-warning behavioral risk intelligence dashboard—Cognivia Signal—empowering clinical teams to see what’s coming before it happens. Mont-Saint-Guibert, Belgium – October 9, 2025 – Cognivia, the AI-driven leader in behavioral science for clinical research, proudly announces the launch of Cognivia Signal, a groundbreaking solution designed to transform how clinical trial sponsors manage behavioral risk.
Many sponsors err on the side of reluctance when incorporating new technology in clinical trials. This is because some technologies have the potential to overly burden not only study operations but also (and most importantly) patients. In this blog, we walk through Cognivia’s approach – and how we make implementing new tech an easy choice.
Experts shared their perspectives from real-world trials on both classical and new approaches to manage the placebo response – and some questions arose throughout the discussion.